Francesco Russo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Francesco Russo has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Emma E. Watson
Department of Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
6 shared publications - Nicolas Winssinger
University of Geneva
6 shared publications - Dimitri Moreau
Department of Organic Chemistry NCCR Chemical Biology Faculty of Sciences University of Geneva 1211 Geneva Switzerland
4 shared publications - Si-Kai Chen
Department of Organic Chemistry, Faculty of Sciences, University of Geneva, Geneva, Switzerland
2 shared publications - Sofia Barluenga
University of Geneva
2 shared publications Dunja Ferring-Appel
European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 27 March 2026
- Published by Springer Nature in Nature Biotechnology
DNA–drug conjugates enable logic-gated drug delivery amplified by hybridization chain reactions
Antibody–drug conjugates enable highly specific delivery of potent cytotoxics to biomarker-expressing cells. In parallel, advances in DNA circuitry and DNA–protein conjugates have allowed programmable integration of molecular inputs and signal amplification via hybridization chain reactions (HCRs). Here we present a system using affibody–DNA and aptamer–DNA conjugates to execute a Boolean logic operation on cell-surface biomarkers, resulting in amplified payload delivery using an HCR of DNA–drug conjugates. Proximity-induced assembly of the biomarker binders generates the initiator that triggers an HCR. The resulting assembly undergoes endocytosis, enabling controlled payload release of drugs conjugated to the DNA with cathepsin-cleavable linkers. We show that DNA–drug conjugates achieve targeted delivery with >100-fold amplification relative to the input biomarkers using fluorescence quantifications. We also identify payloads that strongly influence delivery efficiency and demonstrate delivery of different drug combinations. Finally, we show that biomarker-triggered HCRs can recruit generic antibodies. This modular technology enables tailored combinations of biomarker inputs and drug outputs toward more precise and personalized treatment.
- 27 March 2026
- Published by Springer Nature in Nature Biotechnology
Top Cited PapersOpen AccessDNA–drug conjugates enable logic-gated drug delivery amplified by hybridization chain reactions
Antibody–drug conjugates enable highly specific delivery of potent cytotoxics to biomarker-expressing cells. In parallel, advances in DNA circuitry and DNA–protein conjugates have allowed programmable integration of molecular inputs and signal amplification via hybridization chain reactions (HCRs). Here we present a system using affibody–DNA and aptamer–DNA conjugates to execute a Boolean logic operation on cell-surface biomarkers, resulting in amplified payload delivery using an HCR of DNA–drug conjugates. Proximity-induced assembly of the biomarker binders generates the initiator that triggers an HCR. The resulting assembly undergoes endocytosis, enabling controlled payload release of drugs conjugated to the DNA with cathepsin-cleavable linkers. We show that DNA–drug conjugates achieve targeted delivery with >100-fold amplification relative to the input biomarkers using fluorescence quantifications. We also identify payloads that strongly influence delivery efficiency and demonstrate delivery of different drug combinations. Finally, we show that biomarker-triggered HCRs can recruit generic antibodies. This modular technology enables tailored combinations of biomarker inputs and drug outputs toward more precise and personalized treatment.
- Open Access
- 14 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
DNA-Drug Conjugates (DDCs) for computed delivery
Antibody-drug conjugates (ADCs) offer the potential to deliver potent cytotoxics with unprecedented specificity with respect to a given biomarker. In parallel, development in DNA circuitry and DNA-protein conjugates provide opportunities to design systems that integrate inputs and compute outputs with the potential of amplified responses through hybridization chain reactions (HCRs). Herein, we report a system based on affinity miniproteins (affibodies)-DNA conjugates and aptamer-DNA conjugates to target specific cells via biomarker recognition, yielding a logic-gated response. We demonstrate that this system can be used to trigger HCRs conditionally either on the presence of two biomarkers or based on the density of a single biomarker. Additionally, we show that receptor-mediated uptake of the HCR-generated assemblies can be used to release a combination of payloads. This mechanism successfully achieves the targeted delivery of payloads through a cleavable linker in DNA-Drug conjugates (DDCs), in analogy to ADCs with an added amplification reaching above 100-fold. Crucially, we find that the nature of the drug in DDC is critical for the efficiency of this delivery and that a combination of drugs can be administered simultaneously. Finally, we show that biomarker-triggered HCRs can also be used to recruit generic antibodies.
- 14 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDNA-Drug Conjugates (DDCs) for computed delivery
Antibody-drug conjugates (ADCs) offer the potential to deliver potent cytotoxics with unprecedented specificity with respect to a given biomarker. In parallel, development in DNA circuitry and DNA-protein conjugates provide opportunities to design systems that integrate inputs and compute outputs with the potential of amplified responses through hybridization chain reactions (HCRs). Herein, we report a system based on affinity miniproteins (affibodies)-DNA conjugates and aptamer-DNA conjugates to target specific cells via biomarker recognition, yielding a logic-gated response. We demonstrate that this system can be used to trigger HCRs conditionally either on the presence of two biomarkers or based on the density of a single biomarker. Additionally, we show that receptor-mediated uptake of the HCR-generated assemblies can be used to release a combination of payloads. This mechanism successfully achieves the targeted delivery of payloads through a cleavable linker in DNA-Drug conjugates (DDCs), in analogy to ADCs with an added amplification reaching above 100-fold. Crucially, we find that the nature of the drug in DDC is critical for the efficiency of this delivery and that a combination of drugs can be administered simultaneously. Finally, we show that biomarker-triggered HCRs can also be used to recruit generic antibodies.
- Top Cited PapersOpen Access
- 15 June 2022
- Published by Elsevier in Molecular Cell
- Vol. 82 (14) , 2666-2680.e11
Riboregulation of Enolase 1 activity controls glycolysis and embryonic stem cell differentiation
- 15 June 2022
- Published by Elsevier in Molecular Cell
- Vol. 82 (14) , 2666-2680.e11
Top Cited PapersOpen AccessRiboregulation of Enolase 1 activity controls glycolysis and embryonic stem cell differentiation
- 9 June 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (28)
Titelbild: Optochemical Control of Therapeutic Agents through Photocatalyzed Isomerization (Angew. Chem. 28/2022)
- 9 June 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (28)
Titelbild: Optochemical Control of Therapeutic Agents through Photocatalyzed Isomerization (Angew. Chem. 28/2022)
- Open Access
- 20 May 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (28)
Optochemical Control of Therapeutic Agents through Photocatalyzed Isomerization
A Ru(bpy)3Cl2 photocatalyst is applied to the rapid trans to cis isomerization of a range of alkene‐containing pharmacological agents, including combretastatin A‐4 (CA‐4), a clinical candidate in oncology, and resveratrol derivatives, switching their configuration from inactive substances to potent cytotoxic agents. Selective in cellulo activation of the CA‐4 analog Res‐3M is demonstrated, along with its potent cytotoxicity and inhibition of microtubule dynamics.
- 20 May 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (28)
Open AccessOptochemical Control of Therapeutic Agents through Photocatalyzed Isomerization
A Ru(bpy)3Cl2 photocatalyst is applied to the rapid trans to cis isomerization of a range of alkene‐containing pharmacological agents, including combretastatin A‐4 (CA‐4), a clinical candidate in oncology, and resveratrol derivatives, switching their configuration from inactive substances to potent cytotoxic agents. Selective in cellulo activation of the CA‐4 analog Res‐3M is demonstrated, along with its potent cytotoxicity and inhibition of microtubule dynamics.
- Open Access
- 20 May 2022
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 61 (28) , e202203390
Optochemical Control of Therapeutic Agents through Photocatalyzed Isomerization
A Ru(bpy)3Cl2 photocatalyst is applied to the rapid trans to cis isomerization of a range of alkene‐containing pharmacological agents, including combretastatin A‐4 (CA‐4), a clinical candidate in oncology, and resveratrol derivatives, switching their configuration from inactive substances to potent cytotoxic agents. Selective in cellulo activation of the CA‐4 analog Res‐3M is demonstrated, along with its potent cytotoxicity and inhibition of microtubule dynamics.
- 20 May 2022
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 61 (28) , e202203390
Open AccessOptochemical Control of Therapeutic Agents through Photocatalyzed Isomerization
A Ru(bpy)3Cl2 photocatalyst is applied to the rapid trans to cis isomerization of a range of alkene‐containing pharmacological agents, including combretastatin A‐4 (CA‐4), a clinical candidate in oncology, and resveratrol derivatives, switching their configuration from inactive substances to potent cytotoxic agents. Selective in cellulo activation of the CA‐4 analog Res‐3M is demonstrated, along with its potent cytotoxicity and inhibition of microtubule dynamics.